NBSE NeuBase Therapeutics

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner.

This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until June 3, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until September 30, 2024, to regain compliance with the Rule.

Use of Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by the use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” “project,” or “intend,” the negative of these terms, and similar references to future periods. These forward-looking statements include, without limitation, statements relating to our continued listing on Nasdaq and any exception that may be granted by Nasdaq. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission (the “SEC”), may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: risks relating to the contemplated dissolution and liquidation of the Company, whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses, as well as those risk factors contained in our filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:

Todd Branning

Chief Financial Officer



EN
05/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuBase Therapeutics

 PRESS RELEASE

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely...

 PRESS RELEASE

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on m...

 PRESS RELEASE

NeuBase Therapeutics to Explore Strategic Alternatives

NeuBase Therapeutics to Explore Strategic Alternatives PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company’s business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alte...

 PRESS RELEASE

NeuBase Announces Closing of $5 Million Concurrent Registered Direct O...

NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 578,697 of its shares of common stock (or common stock equivalents) at a purchase price...

 PRESS RELEASE

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ ...

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully redose a gene editor without an immune response Ex vivo data show Stealth Editors™ are titratable, and editing efficiency is in range for clinical benefit in various conditions Company expects to present additional data showcasing gene editing capabiliti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch